Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting
An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to guide recommendations for adjuvant immune checkpoint inhibitor (ICI) therapy. ctDNA helps monitor minimal residual disease and early treatment response while tissue PD-L1 status aids in predicting ICI efficacy, optimizing patient treatment plans.
Video Player is loading.
Video content above is prompted by the following:
- Are you using ctDNA and/or tissue PD-L1 to guide recommendations for adjuvant ICI and/or to monitor response to adjuvant ICI?
Recent Videos
Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing
Adjuvant ICI for High-Risk MIUC: Patient Counseling
Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management
Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies
Dr. Galsky’s Perspectives on the CheckMate 274 Data Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results
Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design
High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy
MIUC: Risk of Recurrence After Radical Cystectomy
Related Content
